What it is
Rusfertide is a synthetic peptide built to do the job of hepcidin, the liver hormone that rations iron. The FDA approved it on 28 August 2026 as Mimrylo (Takeda, NDA 220605), under priority review as a new molecular entity, for erythrocytosis in adults with polycythemia vera (Drugs@FDA, read 2026-11-17). It reached that point under the code PTG-300 from its developer, Protagonist Therapeutics, whose staff co-authored the trial papers.
The label's chemical name describes the molecule exactly (Mimrylo label, section 11, revision 2026-11-07):
| Property | Value | Source |
|---|---|---|
| Chain | 17 amino acids, DTHFPCIKFEPRSKGCK, C-terminal amide | Mimrylo label |
| Ring | Disulfide bond between Cys6 and Cys16 | Mimrylo label |
| Added groups | Isovaleryl cap at the start; palmitoyl-γ-Glu on Lys8 | Mimrylo label |
| Formula (free base) | C114H181N27O28S2 | Mimrylo label |
| Molecular weight | 2,442.0 | Mimrylo label |
| Salt | Acetate | Mimrylo label |
How much of hepcidin is in it. Human hepcidin-25 is DTHFPICIFCCGCCHRSKCGMCCKT (UniProt P81172). Lined up against the label sequence, the first five amino acids, DTHFP, are identical; after that the two diverge (our comparison). Rusfertide has one disulfide bond where hepcidin has four, and carries a fatty-acid chain hepcidin does not. The label gives it as a once-weekly injection.
How it works
Hepcidin controls iron by making cells destroy ferroportin, the channel iron leaves them through — the full mechanism is in the library's hepcidin entry. Rusfertide copies that effect. In polycythemia vera the bone marrow over-produces red cells — production that in health is set by the kidney hormone erythropoietin; restricting iron slows production and lowers haematocrit, the share of blood made of red cells. The standard treatment is phlebotomy, regular blood removal; in both trials the measure of success was how far rusfertide reduced the need for it.
It does not act on the mutated marrow cells that cause the disease. Patients in both trials stayed on their existing treatment, including phlebotomy and, in many, cytoreductive drugs.
What the trials showed
| Trial | People | Design | Result | Source |
|---|---|---|---|---|
| REVIVE, phase 2 | 70 enrolled; 59 randomised in part 2 | 28-week dose-finding, then 12-week randomised withdrawal | Phlebotomies estimated 8.7 a year before vs 0.6 during part 1; response 60% vs 17% placebo in part 2 | Kremyanskaya 2024, NEJM, PMID 38381675 |
| VERIFY, phase 3 | 293 (147 rusfertide, 146 placebo) | 32 weeks, double-blind, on top of standard care | Clinical response 77% vs 33%; phlebotomies 0.5 vs 1.8; haematocrit below 45% in 63% vs 14% | Kuykendall 2026, J Clin Oncol, PMID 42868322 |
| Haemochromatosis, phase 2 | 16 | Open label, no control arm, no prespecified primary endpoint | 15 of 16 phlebotomy-free over 24 weeks (2.31 phlebotomies in the 24 weeks before) | Lancet Gastroenterol Hepatol 2023, PMID 37863080 |
The VERIFY label population was 73% male, mean age 57, and 89% White. Patient-reported fatigue and symptom scores improved more on rusfertide than on placebo (P = .025 and .024). No deaths were reported in the trial.
What the haemochromatosis study can and cannot show: with no control group and no primary endpoint, it is a signal, not proof, and haemochromatosis is not on the label.
Safety on the label
- New or worsening thrombocytosis (high platelets): within four weeks platelets rose by an average of 31%; 36% of patients went above 600 × 10⁹/L and 6% above 1,000 × 10⁹/L. Counts generally levelled off by week 8; 1% stopped the drug for it. The label calls for blood counts every 2 to 4 weeks after starting and after dose changes.
- Injection-site reactions in 56% and anaemia in 16% were the most common adverse reactions.
- Embryo-fetal toxicity: based on animal data the label warns it can cause fetal harm; there are no human pregnancy data.
Where it stands
Rusfertide is a prescription medicine with one approved use. It is not a research peptide, and the label is the only source of dosing figures here, reported as written. Decisions about polycythemia vera treatment belong to a haematologist. ClinicalTrials.gov lists six rusfertide studies (2026-11-17), including a long-term safety extension and phase 2 studies in China and Japan.
Sources opened 2026-11-17: Mimrylo prescribing information (openFDA, revision 2026-11-07); Drugs@FDA NDA 220605; UniProt P81172; Kuykendall et al. 2026 (PMID 42868322); Kremyanskaya et al. 2024 (PMID 38381675); haemochromatosis phase 2, 2023 (PMID 37863080); PubMed E-utilities and ClinicalTrials.gov API v2 counts.
